Atika Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Atika Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-85,000	Closed	-$8.2M	–	100
2023 Q4	$8.2M	Buy	+85,000	New	+$7.52M	1.1%	36
2023 Q1	–	Sell	-73,739	Closed	-$7.63M	–	81
2022 Q4	$7.63M	Buy	+73,739	New	+$6.92M	1.1%	36
2020 Q1	–	Sell	-18,000	Closed	-$1.52M	–	89
2019 Q4	$1.52M	Buy	+18,000	New	+$1.36M	0.29%	65
2019 Q2	–	Sell	-34,500	Closed	-$3.06M	–	80
2019 Q1	$3.06M	Buy	34,500 +500	+1%	+$46.3K	0.62%	58
2018 Q4	$2.9M	Buy	+34,000	New	+$3.23M	0.85%	47
2016 Q4	–	Sell	-35,000	Closed	-$3.24M	–	60
2016 Q3	$3.24M	Buy	+35,000	New	+$3.3M	1.32%	26
2016 Q2	–	Sell	-24,000	Closed	-$1.98M	–	63
2016 Q1	$1.98M	Buy	24,000 +22,000	+1,100%	+$1.79M	1.2%	35
2015 Q4	$210K	Sell	2,000 -30,000	-94%	-$3.13M	0.11%	56
2015 Q3	$3.37M	Buy	+32,000	New	+$4.27M	1.65%	19
2015 Q1	–	Sell	-8,000	Closed	-$723K	–	65
2014 Q4	$723K	Buy	+8,000	New	+$665K	0.53%	56

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Atika Capital Management's BMRN Position: Q1 2024 in Review

Atika Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2024, closing a stake of 85,000 shares — an estimated $8.2M sold.

Atika Capital Management first reported a position in BMRN in Q4 2014 and held it in 10 quarters. The position peaked at $8.2M in Q4 2023. 560 funds tracked by Wall St. Rank hold BMRN as of Q1 2024.

Atika Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Atika Capital Management sold 85,000 BioMarin Pharmaceuticals shares in Q1 2024, an estimated $8.2M.
Atika Capital Management first reported a position in BioMarin Pharmaceuticals in Q4 2014 and held it in 10 quarters.
Atika Capital Management's BioMarin Pharmaceuticals position peaked at $8.2M in Q4 2023.
560 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2024.

Based on Atika Capital Management's 13F filing for Q1 2024, filed 14 May 2024.